17. Pharmacoeconomics. 2018 Mar;36(3):381-382. doi: 10.1007/s40273-018-0620-y.Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-PositiveBreast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.Ansaripour A(1), Uyl-de Groot CA(2), Redekop WK(2).Author information: (1)Institute for Medical Technology Assessment, Erasmus School of Health Policyand Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam,The Netherlands. ansaripour@eshpm.eur.nl.(2)Institute for Medical Technology Assessment, Erasmus School of Health Policyand Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam,The Netherlands.DOI: 10.1007/s40273-018-0620-y PMID: 29427071 